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increased over the years; in 1996 13.7% of the patients started
with at least an equipotent dose of four (simvastatin 20mg or
equipotent) while in 2004 88.4% of all patients started on at
least an equipotent dose of four. Goal attainment increased from
42% in years prior to 2001 to 59% in 2002–2004 and was high
in patients with cardiovascular disease and diabetes (43% versus
69%). CONCLUSIONS: Although in recent years aggressive
statin treatment and lower baseline TC levels led to higher goal
attainment 41% of the patients still did not reach goal. There-
fore even more effective and well tolerated lipid lowering thera-
pies seem to be required.
PCV44
COST-EFFECTIVENESS OF ROSUVASTATIN IN THE
PREVENTION OF ISCHEMIC HEART DISEASE IN PORTUGAL
Gouveia-Pinto C1, Carrageta M2, Silva-Miguel L3
1Instituto Superior de Economia e Gestão,Technical University of
Lisbon, Lisbon, Portugal; 2Garcia de Orta Hospital, Almada, Portugal;
3Research Centre on the Portuguese Economy—CISEP, Lisbon,
Portugal
OBJECTIVES: To analyse the cost-effectiveness of Rosuvastatin
compared to Atorvastatin in the treatment of hypercholes-
terolemia and prevention of ischemic heart disease (IHD) in 
Portugal. METHODS: A probabilistic Markov model was devel-
oped to analyse the costs and consequences of lifetime treatment
with Rosuvastatin and Atorvastatin. For this purpose, results
from head-to-head, randomised, double-blind trials evaluating
low-density lipoprotein (LDL) changes and from a meta-analy-
sis deﬁning the relationship between LDL levels and fatal and
non-fatal IHD events were combined. Incidence of myocardial
infarction was derived from a nine-year Portuguese observa-
tional study. Death rates due to IHD and other causes were
obtained from ofﬁcial data. Resource use in the treatment of MI
was estimated by a Delphi panel of 8 Portuguese cardiologists
with at least 15 years of clinical practice. Calculation of costs
was done on both the societal and patients’ perspectives. Eligi-
ble population was deﬁned as untreated individuals over 35 years
of age with LDL above 160mg/dl. RESULTS: Rosuvastatin
slightly increases life expectancy: 5.64 days per patient and 8832
years for the eligible population. Although the drug is more
expensive, economic analysis shows that Rosuvastatin is cost
saving. It saves €105 or €57 per patient on the society’s or the
patients’ perspective, respectively. Therefore, Rosuvastatin dom-
inates the alternative having a cost-effectiveness ratio of -€6772
and -€3682 per life year according to the society’s or the
patients’ perspectives. In the 10,000 simulations carried out
Rosuvastatin was always more efﬁcacious than Atorvastatin,
being cost saving in 56.05% of the cases. If the willingness to
pay is higher than €162 (society) or €98 (patients) Rosuvastatin
is cost-effective in all cases. CONCLUSION: Rosuvastatin dom-
inates Atorvastatin in the prevention of IHD in Portugal.
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While treatment guidelines recommend lowering cholesterol 
to target levels, many remain above recommended goal (TC 
>4.5mmol/dl for CHD and diabetic patients). In a clinical trial
patients switched from statin monotherapy to Ezetimibe/Sim-
vastatin (dual inhibition therapy) experienced an additional
27.5% and an 18.8% reduction in LDL-C and TC, respectively.
OBJECTIVE: Assess cost-effectiveness of switching patients to
Ezetimibe/Simvastatin (followed by titration on Ezetimibe/
Simvastatin) versus an atorvastatin dose titration strategy in
CHD/diabetic patients who are not at goal with atorvastatin
monotherapy. METHODS: Previously published decision-ana-
lytic model was used to project lifetime costs and beneﬁts of lipid
therapy. Clinical trial data were used in the model to estimate
TC reductions for different treatment strategies. The effect of TC
reductions on CHD event rates was estimated using Framingham
equations and Finnish statistics on nonCHD-related mortality.
Direct costs of CHD events in Finland [Health 2000 Survey data
at the 2003 price level and also from the literature], Finnish
prices for atorvastatin and Ezetimibe/Simvastatin and age spe-
ciﬁc quality-of-life weights were used to project cost/QALY. The
model was run for a sample of Finnish CHD/diabetic patients
(N = 25) that participated in the Finrisk 2002 study and were
not at TC goal while on therapy with atorvastatin and having
data on all Framingham risk factors. RESULTS: The mean age
of the study sample was 60.4 (SD 7.7) years, 60% male, lipid
proﬁle on atorvastatin TC 5.4 (SD 0.9) mmol/L, HDL-C 1.3 (SD
0.3) mmol/L, triglycerides 1.8 (SD1.1) mmol/L. Switching to 
Ezetimibe/Simvastatin (followed by 11% titration on Ezetimibe/
Simvastatin) compared to atorvastatin titration (11%) is pro-
jected to increase undiscounted life expectancy by 0.75 years for
CHD/diabetic patients with a discounted incremental cost/QALY
of €9172. CONCLUSION: Switching to dual inhibition therapy,
(Ezetimibe/Simvastatin) in CHD/diabetic patients not at goal on
atorvastatin is projected to be a cost-effective alternative to ator-
vastatin titration.
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OBJECTIVES: The aim of this study was to collect comparable
and reliable data on the lipid lowering therapy in Slovakia during
the period 1996–2004. The special interest was paid to the trend
of the statin and ﬁbrate usages. METHODS: Data of wholesalers
(following ATC/DDD), who are legally obliged provide this
information to the Slovak Institute for Drug Control, was used
for the analysis. The results were expressed in the numbers of
the packages, ﬁnance units (€) and deﬁned daily doses per 1000
inhabitants per day (DID). RESULTS: The collected data showed
large increases in hypolipidemic consumption from 1996 to 2004
in term of DID (in 1996 (4.18), in 2000 (12.79) and in 2004
(31.50)). A signiﬁcant increase in statin consumption (in 1996
(1.97), in 2000 (6.27) and in 2004 (22.33)) and slight increase
in ﬁbrate consumption (in 1996 (3.59), in 2000 (6.38) and in
2004 (9.13)) in term of DID can be seen from this analysis. From
the reimbursement point of view, simvastatin (in 2000 was reim-
bursed at the level of €0.84 per DDD, in 2004 the reimburse-
ment level was at €0.24), ﬂuvastatin (in 2000 was reimbursed at
the level of €0.75 per DDD, in 2004 the reimbursement level was
at €0.47), atorvastatin (in 2000 was reimbursed at the level of
€0.89 per DDD, in 2004 the reimbursement level was at €0.51).
Financial expenditures were for statins (in 1996 (€989,000), in
2000 (€10,335,000) and in 2004 (€13,043,000)) and for ﬁbrates
(in 1996 (€2,743,000), in 2000 (€4,546,000) and in 2004
(€4,478,000)). CONCLUSIONS: Usage of generic drugs for the
treatment of hypercholesterolemia brought about a dramatic
increase in hypolipidemic consumption and the ﬁnancial expen-
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ditures for health insurance funds have been remained under
control.
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OBJECTIVES: POLARIS is a 26-week, double-blind, ran-
domised study comparing the efﬁcacy of rosuvastatin (RSV) 
40mg with atorvastatin (ATV) 80mg in high-risk patients
(known CHD or CHD-risk equivalent, as deﬁned by NCEP ATP
III) with hypercholesterolaemia. Using a secondary prevention
model, results from POLARIS were used to estimate longer-term
costs and beneﬁts. METHODS: Efﬁcacy data from POLARIS
(TC, HDL-C, and TG) were used as input to the model. Markov
models were run in 4-year cycles over 20 years, from age 55 to
76 years for men and women separately. Secondary CHD risk
was based on Framingham data (d’Agostino et al. AHJ 2000)
but calibrated to British Regional Heart Study (Brindle et al. BMJ
2003). Estimates for life expectancy, health-care costs and
quality-adjusted life years (QALYs) were assigned to patients as
they transitioned through the model. RESULTS: RSV 40mg
improved levels of TC and HDL-C more than ATV 80mg (-41%
vs. -39%; +11.0 vs. +6.2%, respectively).The model predicts
that more secondary CHD events and deaths are avoided 
with RSV 40mg compared with ATV 80mg in both high-risk
men and women; hence, more life-years and QALYs are gener-
ated and event costs are lower. More patients survive on treat-
ment and therefore total costs with RSV 40mg are slightly
higher. Cost per life year gained (men: £1113, women: £1065)
and QALY gained (men: £2091, women: £3079) are favourable
for RSV 40mg. CONCLUSIONS: RSV 40mg is likely to be more
effective both clinically and economically than ATV 80mg for
the secondary prevention of CHD.
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While treatment guidelines recommend lowering cholesterol to
target levels, many remain above goal (LDL-C >100mg/dL for
CHD/diabetic patients and LDL-C >130mg/dl for other non-
CHD high risk individuals). OBJECTIVE: To assess the change
in LDL-C and goal attainment rates due to switching patients to
an Ezetimibe/Simvastatin dose titration strategy, compared with
a simulated statin monotherapy dose titration strategy.
METHOD: A decision-analytic model was developed to project
goal attainment at end of 1-year after therapy change. Clinical
trial data were used to estimate LDL-C reductions for different
treatment strategies. The model was run for a population of 504
Spanish patients (237 CHD/diabetic and 267 non-CHD high risk
patients) that had not reached LDL-C goal levels 3-months after
starting statin therapy. Patients not at goal where up titrated (till
goal attainment or to the maximum dose whichever was ﬁrst)
every 3 months both in the Ezetimibe/Simvastatin (only simvas-
tatin titrated) and in the statin monotherapy titration arms.
RESULTS: Mean age was 60.8 (SD 9.8) years, 47.8% female,
lipid proﬁle (mg/dl) at three months on statin monotherapy was
LDL-C 182.3 (SD 35.1), TC 262.1 (SD 39.5), HDL-C 50.8 (SD
14.1), triglycerides 150.1 (SD 82.5). Ezetimibe/Simvastatin
therapy is projected to achieve a 82.6% goal attainment rate,
compared with 46.0% projected for the statin titration strategy.
With respect to LDL-C reductions, Ezetimibe/Simvastatin would
achieve a 38.2% reduction over baseline, compared with a
24.5% with the statin titration strategy. In the statin arm, 73.9%
of the patients reached the statin maximum dose, whereas in the
Ezetimibe/Simvastatin arm, only 23.5% of the patients did so.
CONCLUSION: Compared to statin monotherapy titration,
switching patients not at goal on statin monotherapy to Ezetim-
ibe/Simvastatin followed by titration is projected to get 36.6%
additional patients to goal and reduce LDL-c by 13.7%.
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OBJECTIVE: The objective of this study was to describe the
burden of modiﬁable risk factors and of the total CV risk in a
population, free of CVD, selected in general practice, on the basis
of age (40–75yrs) and waist circumference (>=94cm in men and
>=80cm in women). METHODS: In total, 619 Belgian GPs
recruited consecutive patients during spring 2004. A central lab
analysed fasting blood samples. RESULTS: Complete data on
8587 patients were obtained. Mean age was 58yrs (47%
women). Mean BMI and waist were 30.1kg/m2 and 99cm for
women and 30.1kg/m2 and 107cm for men. Eighteen-percent
had diabetes (D) either known and treated (14%) or newly
detected, based on fasting glucose levels (4%). Of the non-
diabetic subjects (ND), 25% had ° 3 metabolic syndrome risk
factors (NCEP-ATP III criteria). Twenty-four percent of the total
population was smoking and 84% did not engage in regular
physical activity. Seventy-seven percent of ND had LDL 
cholesterol >=115mg/dl & 78% of D had LDL cholesterol
>=100mg/dl. Only 31% of subjects on lipid lowering drugs had
TC < 190 and LDL <115mg/dl. 49% of ND had BP >=140/90
mmHg and 91% of the D had BP >=130/80mmHg. Total CV
risk in the ND was estimated using the SCORE chart calibrated
for Belgium. Total risk >=5% for dying from CVD in the coming
10yrs was present in more than 40% of men and in more than
20% of women. CONCLUSION: Waist measurement is an easy
and inexpensive tool to detect, in the middle-aged population
free of CVD, a subgroup with a large variety of modiﬁable risk
factors and at high risk for CV death. A large majority of them
is physically inactive, an unacceptable proportion is smoking and
both total cholesterol and blood pressure are insufﬁciently
managed.
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OBJECTIVES: The main aim is to evaluate the variability of
practitioners’ prescribing behaviour on statines in AUSL Bologna
South from 2000 to 2003, as well as to quantify how much such
a behaviour depends on culture, education and policy of practi-
tioner. METHODS: A multilevel model has been built to reﬂect
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